-
A second NS3/4A protease inhibitor has been approved by the FDA for the treatment of chronic hepatitis C (HCV) genotype 1, joining the recently approved boceprevir (Victrelis). Telaprevir is marketed by Vertex Pharmaceuticals as Incivek.
-
A very low energy diet followed by a weight maintenance program results in significant improvements in weight, obstructive sleep apnea, metabolic factors, and quality for at least a year.
-
Elders who ate sorbet before a meal ate more of the rest of their meal.
-
-
-
In this study of a large administrative database, the incidence of selected complications in patients diagnosed with sleep apnea (SA) was compared to that in patients undergoing similar surgical procedures who were not diagnosed with SA.
-
Current guidelines for the use of emergency oxygen recommend its judicious use in patients with obesity-associated hypoventilation (OAH) in order to avoid worsening hypercarbia, but these guidelines have largely been based on anecdotal clinical experience rather than systematically collected evidence.
-
In this issue: Two new drugs for treatment of hepatitis C; NSAIDs and myocardial infarction risk; AIM-HIGH clinical trial stopped; and FDA actions.
-
The purpose of this prospective, observational study was to report on the feasibility and safety of limiting sedation throughout a patient's ICU stay.
-
A wide variety of resources have been developed over the last several years, primarily Internet-based, to assist the critical care provider in managing patients in the ICU.